Search

Now showing items 1-1 of 1

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).

Mehra, N; Dolling, D; Sumanasuriya, S; Christova, R; Pope, L; Carreira, S; Seed, G; Yuan, W; Goodall, J; Hall, E; Flohr, P; Boysen, G; Bianchini, D; Sartor, O; Eisenberger, MA; Fizazi, K; Oudard, S; Chadjaa, M; Macé, S; de Bono, JS (2018-09)

BACKGROUND:Noninvasive biomarkers are needed to guide metastatic castration-resistant prostate cancer (mCRPC) treatment. OBJECTIVE:To clinically qualify baseline and on-treatment cell-free DNA (cfDNA) concentrations as ...